|
Volumn 3, Issue 7, 2012, Pages 829-835
|
Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases
b
Nycomed GmbH
(Germany)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BELINOSTAT;
ENTINOSTAT;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ERLOTINIB;
ERLOTINIB DERIVATIVE;
HISTONE DEACETYLASE;
HISTONE DEACETYLASE INHIBITOR;
MOCETINOSTAT;
PANOBINOSTAT;
PROTEIN TYROSINE KINASE INHIBITOR;
UNCLASSIFIED DRUG;
VORINOSTAT;
ANIMAL CELL;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER RESISTANCE;
CONTROLLED STUDY;
DRUG DESIGN;
DRUG DEVELOPMENT;
DRUG RESISTANCE;
ENZYME INHIBITION;
HUMAN;
HUMAN CELL;
IC 50;
NONHUMAN;
PRIORITY JOURNAL;
|
EID: 84863649774
PISSN: 20402503
EISSN: 20402511
Source Type: Journal
DOI: 10.1039/c2md00317a Document Type: Article |
Times cited : (32)
|
References (32)
|